CrownBio will present data on its latest scientific developments including the impact of intestinal microbiota on anti-PD-L1 immunotherapy, the development of primary tumor allograft models for pre...
CrownBio’s clients will now be able to purchase hundreds of products on-line across a portfolio consisting of: antibodies for in vivo and in vitro studies, recombinant proteins and cell lines, immu...
CrownBio clients will be now able to manage their internal patient-derived xenograft (PDX) portfolio on the model of CrownBio’s bespoke HuBase technology platform.